8Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol, 2007, 8 : 15-27.
9Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 2001,97:3658-3661.
10Mouroux J, Padovani B, Elkaim D, et al. Should cavitated bronchopulmonary cancers be considered a separate entity? Ann Thorac Surg, 1996, 61:530-532.